|
|||||
|
Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter |
Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
DGX | BALDWIN JOHN C MD | Director | Aug 12 | Sale | 72.00 | 2,266 | 163,152 | 12,949 | Aug 13 04:49 PM |
DGX | BALDWIN JOHN C MD | Director | Jul 29 | Option Exercise | 55.76 | 8,000 | 446,080 | 20,875 | Jul 29 04:44 PM |
DGX | BALDWIN JOHN C MD | Director | Jul 29 | Sale | 62.31 | 8,000 | 498,480 | 12,875 | Jul 29 04:44 PM |
DGX | BALDWIN JOHN C MD | Director | Nov 05 | Sale | 63.00 | 658 | 41,454 | 9,951 | Nov 05 04:33 PM |
DGX | BALDWIN JOHN C MD | Director | Oct 31 | Option Exercise | 51.55 | 8,000 | 412,400 | 18,609 | Nov 04 04:39 PM |
DGX | BALDWIN JOHN C MD | Director | Oct 31 | Sale | 59.70 | 8,000 | 477,600 | 10,609 | Nov 04 04:39 PM |
DGX | BALDWIN JOHN C MD | Director | May 14 | Sale | 59.41 | 1,214 | 72,122 | 8,634 | May 15 04:39 PM |
DGX | BALDWIN JOHN C MD | Director | Aug 08 | Option Exercise | 55.40 | 10,000 | 554,000 | 21,618 | Aug 09 04:18 PM |
DGX | BALDWIN JOHN C MD | Director | Aug 08 | Sale | 60.00 | 11,770 | 706,165 | 9,848 | Aug 09 04:18 PM |
DGX | BALDWIN JOHN C MD | Director | May 01 | Option Exercise | 49.94 | 8,000 | 399,520 | 19,977 | May 03 04:33 PM |
DGX | BALDWIN JOHN C MD | Director | May 01 | Sale | 57.50 | 10,334 | 594,205 | 9,643 | May 03 04:33 PM |
DGX | BALDWIN JOHN C MD | Director | Jan 26 | Option Exercise | 53.27 | 10,000 | 532,675 | 21,977 | Jan 30 04:39 PM |
DGX | BALDWIN JOHN C MD | Director | Jan 26 | Sale | 59.00 | 10,000 | 590,005 | 11,977 | Jan 30 04:39 PM |
DGX | BALDWIN JOHN C MD | Director | Feb 09 | Option Exercise | 44.76 | 30,000 | 1,342,900 | 40,002 | Feb 10 05:06 PM |
DGX | BALDWIN JOHN C MD | Director | Feb 09 | Sale | 57.56 | 30,000 | 1,726,881 | 10,002 | Feb 10 05:06 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite